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1.      INTRODUCTION 
  
1.1 Phenylketonuria: the PAH gene and enzyme and the 
disease-causing mutations 
 
Phenylketonuria (PKU) is one of the most common inherited metabolic diseases 
(IEM). The incidence is approximately 1:10,000 Caucasian live births (OMIM 
261600) and is caused by a deficient activity of phenylalanine hydroxylase (PAH; 
EC 1.14.16.1), a non-heme iron-dependent enzyme that catalyzes the 
hydroxylation of L-phenylalanine (L-Phe) to L- tyrosine (L-Tyr) in the presence 
of (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) and molecular dioxygen as 
cosubstrates (1) (Figure 1). 
 
Figure 1: Reaction catalyzed by the PAH. The enzyme PAH converts Phe to Tyr using 
BH4 and oxygen. BH4 is recycled via a two-step pathway which utilizes NADH. 
The PAH gene contains 13 exons and maps on chromosome 12q22-q24.1. 
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The enzyme assembles into homotetramers, with each subunit consisting of three 
domains: an N-terminal regulatory domain (residues 1–142), a large catalytic 
domain (residues 143–410) and a C-terminal domain (residues 411–452) that is 
responsible for tetramerization and includes a dimerization motif (411–426) (1) 
(Figure  2). 
 
 
 
 
 
Figure 2: PAH gene and enzyme. The PAH gene maps onto chromosome 12q22-q24.1 
(Panel A). Each PAH monomer consists of an N-terminal regulatory domain (blue), a 
large catalytic domain (yellow) and a C-terminal domain (green) (Panel B,1). The active 
enzyme derives from the association of 4 monomers (Panel B,2). 
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In humans, liver PAH activity provides L-Tyr for protein and neurotransmitter 
biosynthesis, it is involved in energy metabolism, and most importantly, it 
prevents plasma L-Phe accumulation, which is toxic to the brain (2,3).  
As a consequence, a defective activity of PAH leads to hyperphenylalaninemia 
(HPA), that, according to the magnitude of the increase in blood Phe, can be 
classified as: mild HPA (MHP), mild or variant PKU and classical PKU (1).  
The defective activity of PAH depends on mutations of the PAH gene. 
To date, more than 500 disease-causing mutations have been discovered and are 
listed in PAHdb at http://www.pahdb.mcgill.ca/. The majority of these are 
scattered over the entire gene length but with a different frequency in distinct 
populations and geographic areas (4-9) and a number of them have been analyzed 
and characterized (10-12). Thanks to these studies, it is now known that most of 
PAH missense mutations result in a misfolding of the protein which increases its 
turnover both in vitro and probably in vivo, pointing to a decreased 
conformational stability as the major molecular mechanism for the loss of PAH 
function in PKU (13). 
Recently, it has been discovered that some PAH mutations are responsive to BH4 
treatment. These mutations show a residual enzymatic activity that is associated 
with BH4 responsiveness (14-15). Patients with these mutations show an 
improvement in their clinical conditions after oral administration of BH4 because 
their mutant enzymes suppress the low binding affinity for BH4, enabling the L-
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Phe hydroxylation reaction. Most of these BH4-responsive PAH mutations map to 
the catalytic domain of PAH, in cofactor-binding regions or in regions that 
interact with the secondary structural elements involved in cofactor binding.  
In a small cohort of HPA patients, no PAH mutations have been found and the 
disease has been related to a lack of the BH4, due to defective cofactor 
biosynthesis and regeneration. This group, however, represents only 1% of all 
HPA cases (16).  
  
1.2 PKU brain pathology 
 
 
In most industrialized countries, HPA is diagnosed during newborn screening 
programs (17), with a remarkable success in preventing the major manifestations 
of the disease that, as stated above, are due to brain injuries. 
In fact, L-Phe accumulation is associated with a phenotype presenting with 
growth failure, microcephaly, seizures, and mental retardation (2,3).  
To date, despite the large number of studies, the pathogenesis of brain dysfunction 
in PKU is still unclear. However, it is known that L-Phe interferes with various 
cerebral enzyme systems, such as tyrosine hydroxylase and tryptophan 
hydroxylase, influencing neurotransmitter synthesis (18) and causing a decrease 
of brain amine contents (19), as well as HMG-CoA reductase, thus resulting in 
impaired cholesterol synthesis (20). High concentrations of L-Phe have also been 
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related to a reduction of glutamatergic and glutaminergic synaptic transmissions 
(21,22),  synaptogenesis and activity of the pyruvate kinase enzyme(23).  
Other studies have shown that glucose metabolism is low in the brain of 
phenylketonuric patients, so altering the normal energy metabolism (24,25,26).  
Moreover, increased levels of L-Phe seems also to cause a reduction of the other 
large neutral aminoacids (LNAA), probably because of a competition for the same 
transporter through the blood brain barrier (27-31).  
To complete this overview on PKU brain pathology, recent in vitro and in vivo 
studies have highlighted a role of oxidative damage elicited by L-Phe and its 
derivates in rat brain (32).  
 
1.3 PKU maternal syndrome 
 
Another problem associated with PKU is the so called maternal syndrome. This  
syndrome is caused by high L-Phe levels during pregnancy and presents an 
incidence of 1/30000-40000 gestations. Increasing levels of L-Phe in pregnant 
PKU women cause severe teratogenic effects in the fetuses that can develop 
microcephaly, mental retardation (75-90%) and congenital heart disease (15%) 
(33) (Figure 3).  
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Figure 3: Maternal PKU syndrome. The maternal syndrome derives from the 
exposition of the fetus to the maternal elevated Phe levels that cross the placental barrier 
causing birth defects. 
 
Many hypothesis regarding the pathogenesis of PKU maternal syndrome have 
been proposed:  some authors believe that the damage is due to the transport of 
aminoacids across the placental barrier (34), whereas others focus on the direct 
damage of alternative products of L-Phe metabolism on fetal organs (35).  
According to the first hypothesis, fetuses may lack sufficient aminoacids to 
perform an optimal protein synthesis because excessive amounts of L-Phe inhibit 
the transport of aminoacids such as tyrosine, isoleucine, valine and methionin. 
The second hypothesis instead is based on the damage deriving from the 
exposition of fetuses to alternative L-Phe metabolites such as  phenylacetic acid, 
phenylethilamine or a combination of both. This second hypothesis reduces the 
role of L-Phe in the development of fetus abnormalities. By the way, some 
evidences seem to support the first hypothesis, consisting in the  direct role of L-
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Phe; in fact, analysing fetal tissues, it is possibile to observe that while L-Phe is 
present in great amounts, L-Phe metabolites are present only in minimal amounts. 
A major support to the first hypothesis is also given by the observation that 
women with defects in the accumulation of L-Phe metabolites have normal 
chidren. This demonstrates that L-Phe is the real teratogenic agent and that it  
causes fetal abnormalities alone or in association with its alternative metabolites.  
As mentioned before, HPA is diagnosed in newborn screening programs (17) that 
avoiding  the development of neuronal damage in babies born with PKU and 
allowing an increasing number of people with the disease to reach adulthood, to 
work and to form relationships. However, it is also evident that, thanks to this 
newborn screening, a greater number of  healthy PKU women of child−bearing 
age exist. These women are at high risk of having babies with mental and physical 
impairments if they do not control their L-Phe levels. For this reason, PKU 
women must plan eventual gestations and, if they should decide to have children, 
they must consult specialized centres at least six months before gestation to 
discuss the treatment with experts. In fact, if the gestation has not been planned 
and L-Phe levels remain high in the first eight weeks, PKU women are at risk of 
having babies with severe defects which cannot be avoided even if L-Phe is 
strictly monitored (36).   
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1.4 PKU actual treatment: the low Phe diet 
 
As stated in 1.2 and 1.3 sections, PKU related symptoms are severe, therefore it is 
necessary to treat this disease since birth.  
At present, PKU is treated with a lifelong dietary protein restriction (37), in which 
many common foods, such as milk and dairy products, meat, eggs, wheat, beans, 
corn, peanuts, lentils, and other grains, are prohibited to the patients. 
The diet consists of drinkable formulas, synthethically made as nutritional 
substitutes for all the eliminated foods, containing no Phe but all the necessary 
vitamins, minerals, aminoacids. Moreover, it allows low protein special foods and 
measured amounts of fruits, vegetables and grain products (Figure 4).  
 
 
Figure 4: Low Phe diet. Foods that are allowed are in the inner part of the 
diagram (white circle).  
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In the past, it was common for children to be taken off the diet between 6 and 10 
years of age, when brain development was considered to be completed, however, 
discontinuation of the diet resulted in many serious problems such as: 
1. deterioration of intellectual quotient, 
2. learning disabilities,  
3. behavioural problems (hyperactivity, irritability, self abusing behaviours), 
4. neurological impairments (severe tremors, epilepsy resistant to 
anticonvulsivant therapy, spastic paraparesis and quadriparesis with the 
risk of becoming wheel chair bound), 
5. eczema, 
6. personality disorders (schizophrenia, panic attacks). 
It is now a common knowledge that dietary therapy must be followed for life but 
it has been shown that Phe levels within the recommended range are achieved by 
70% of the children younger than 10 years but only by 20% of those 15 years and 
older.  
Therefore, despite being a huge advance and generally effective, a low Phe diet 
cannot be considered the dream management for PKU patients, and a number of 
different approaches have been developed in the last few years towards an 
alternative treatment for PKU. Thanks to the availability of a good animal model 
for this pathology, it has been possible to experimentally explore new treatments 
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for PKU that, in some cases, seem to be really promising for the treatment of the 
disease. 
 
1.5 PKU animal models  
 
The first animal model that was proposed for PKU was represented by rats to 
which phenylalanine analogues had been administered as PAH inhibitors to 
suppress the enzyme activity. However, the results were complicated by side 
effects of these inhibitors (38). More successful was the chemical mutagenesis of 
a BTBR-mouse strain using the alkylating agent N-ethyl- N-nitrososurea (ENU) 
that resulted in the isolation of a hyperphenylalaninemic mouse with a mutation 
called Pahenu2 (39) (Figure 5). 
 
Figure 5: Murine model of PKU. Phenylketonuric mice are simply recognized for their 
characteristic greyish coat color (left side of the picture). Normal mice present a black 
coat (right side of the picture). 
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The Pahenu2 allele was genetically mapped to the Pah locus and sequence 
analysis revealed a missense mutation at exon 7, in the region encoding the active 
site of the enzyme, which is by far the most frequent mutation site for PKU in 
humans. 
Besides hyperphenylalaninemia, this mouse presented many symptoms observed 
in PKU patients, namely: slow growth, small head, hypopigmentation, 
behavioural disturbances and maternal PKU syndrome (40,41). Genetics and 
biochemistry have demonstrated the reliability of this animal as model for human 
PKU . 
Thus, most PKU-animal studies, if not all, in somatic gene therapy and enzyme 
replacement, have been carried out in this Pahenu2 mouse model and provided 
valuable information on the biology and pathology of PKU.  
Besides these studies, focused on the discovery of new strategies to treat PKU, 
these mice have been also a model for investigating PKU brain pathology as they 
present a decrease of the amine contents from the thirth to the fifth week of life 
(42), impairments of the glutamatergic synaptic transmission (22), pathologic 
alterations in the hypothalamic and mesencephalic regions that begin at four 
weeks of age (43) and evidences of a reversible neurodegeneration in the nigro-
striatal area at the same age (44). 
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Moreover, PKU mice also show a severe behavioural phenotype, with deficits 
involving both spatial and non-spatial recognition that are not related to motor 
impairments or to high emotional reactivity to novelty (45).  
 
1.6 Alternatives approaches to  PKU treatment 
 
 
As mentioned in 1.4 section, PKU related symptoms can be prevented by a strict 
dietary restriction from early infancy. Although it is recognized that dietary 
treatment initiated early in life is successful in avoiding the severe mental 
retardation of PKU, this treatment presents many limitations, since PKU patients 
must adhere to an unpalatable, expensive and lifelong diet (37) that is frequently 
stopped prematurely, leading to an unsatisfactory clinical outcome (33,46,47). 
Therefore, alternatives to the diet such as protein substitutes with a more pleasant 
flavour (48), Phe-ammonia lyase administration (49), large neutral aminoacids 
supplementation (50) and gene therapy (51-55) have been proposed.  In particular, 
gene therapy is a very promising approach for the treatment of PKU. 
Several vectors have been used at this purpose including first generation 
adenoviral (FG−Ad) vectors, integrating vectors and adeno−associated vectors 
(AAV) (56).  
FG−Ad vectors have been able to efficiently rescue the phenotype of PKU but for 
a very short period because of the strong immune response that followed their in 
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vivo administration (51,52). Fang et al. (51) used a recombinant adenoviral vector 
containing the human PAH-cDNA under control of the Rous sarcoma virus long- 
terminal repeat (RSV-LTR). The recombinant virus was injected into the liver 
through the portal vein of the PKU mouse. A complete normalization of the serum 
phenylalanine levels and a significant increase of PAH activity was obtained in 
these PKU mice within one week of treatment. Unfortunately, the therapeutic 
effect of the adenoviral vector delivery did not persist beyond a few weeks, and 
repeated administration did not reproduce the original results due to the 
neutralizing antibodies against the adenoviral vector. Furthermore, this study did 
not rescue other phenotypic changes such as for instance hypopigmentation. 
However, an important finding from this study was that 10–20% of normal PAH 
enzymatic activity was sufficient to restore normal serum phenylalanine levels.   
In another study, a recombinant FG−Ad vector containing the strong CAG-hybrid 
promoter was constructed to drive expression of the human PAH gene in the PKU 
mouse to potentially enhance treatment efficacy (52). Also in this case, the 
therapeutic effect did not persist beyond few weeks but suppression of the host 
immune response by administration of the immunosuppressant FK506 allowed 
repeated gene delivery, resulting in moderately prolonged PAH gene expression 
and reversal of hypopigmentation. 
Integrating vectors, on the other hand, have shown a prolonged duration of 
expression compared to FG−Ad vectors.  An early approach that was done for 
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PKU treatment consisted of the transduction via recombinant retroviral vectors of 
the PAHcDNA into hepatocytes isolated from the PKU mouse (53,54). The PAH 
gene was efficiently transferred and expressed at high levels in these primary 
hepatocytes, however, the risk of mutagenesis for these vectors is unacceptable 
for a disease with an alternative diet therapy.   
AAV vectors have, at the moment, provided the best results for gene therapy of 
PKU even if they present some limitations such as the small cargo capability, the 
need to find the right serotype to increase hepatocytes transduction and the 
different therapeutic response after the injection of the AAV vector between 
males and females. In fact, in initial trials (55), only male mice responded to the 
AAV mediated therapy by lowering phenylalanine to therapeutic levels, whereas 
females were unresponsive unless they were ovariectomized and treated with 
testosterone. This limitation was overcame with following studies (56), obtaining 
a normalization also in female mice, even though higher doses of the therapeutic 
vector were necessary to achieve a phenotypic correction. 
 
1.7 The potential of adenoviral vectors as liver directed 
gene delivery systems  
 
A crucial factor for the proposal of a gene therapy strategy to treat PKU is the 
choice of an appropriate vector. Each of the vectors currently used possesses a 
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unique set of characteristics that renders it most suited for specific applications in 
gene therapy. 
In particular, among viral vectors, those deriving from adenoviruses seem to be 
really promising for the treatment of pathologies whose defect is in the liver. This 
particular feature derives from the natural tropism that adenoviruses show for 
hepatocytes after intravenous delivery (57). Numerous demonstrations of 
adenoviral vector-mediated delivery of a wide array of transgenes in several 
animal species and in humans have been reported and many examples of liver 
pathologies have been successfully treated by adenoviral vector-mediated gene 
therapy (58). In fact, many liver diseases lack satisfactory treatment and 
alternative therapeutic options are needed. A considerable number of preclinical 
studies indicate that a great variety of liver diseases, including inherited metabolic 
defects, chronic viral hepatitis, liver cirrhosis and primary and metastatic liver 
cancer, are amenable to gene therapy treatments with adenoviral vectors. 
Moreover, gene transfer to the liver can also be used to convert this organ into a 
factory of secreted proteins needed to treat conditions that do not affect the liver 
itself.  
For all these reasons, the treatment of PKU with adenoviral vectors seems to be a 
very promising approach to cure this disease, especially because recent 
developments in these vectors have originated a very safe system ( named helper  
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dependent adenoviral vectors) that is able to mediate high-efficiency transduction 
and to direct sustained high-levels of transgene expression with negligible chronic 
toxicity (59-60) 
 
1.8 Adenoviruses 
 
 
Adenoviral vectors derive from modifications of wild type adenoviruses. 
Adenoviruses were first discovered more then 50 years ago by Rowe and 
colleagues from human adenoid cells (61). They have a linear, double stranded 
DNA of about 36 kb surrounded by a protein structure with an icosahedral shape 
named capsid (Figure 6). 
 
Figure 6: Adenovirus structure: a three-dimensional image reconstruction of Ad5. 
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The adenoviral virion is a non-enveloped particle about 70-90 nm in size with an 
outer protein shell (capsid) surrounding an inner nucleoprotein core. The 
icosahedral capsid consists of 252 capsomers divided in 240 hexons and 12 
pentons. Each hexon is composed of three monomeric polypeptides (polypeptide 
II) forming the 20 triangular facets of the capsid; the penton, instead, shows a 
more complex structure, constituted by five monomeric polypeptides (polypeptide 
III), which act to anchor a trimeric protein, the fiber (polypeptide IV). The penton 
and the fiber form the penton complex that seals the capsid attach of the 12 virion 
vertices. These proteins are responsible for the attachment (fiber) and 
internalization (penton) of the virus into host cells.  
The capsid is composed also of a number of other minor components including 
protein IIIa, pVI, pVIII and pIX. Adenovirus cores contain the viral genome, a 
linear, double strended DNA that is approximately 36 kb long. Each end of the 
genome has an inverted terminal repeat (ITR) of 100-140 bp with a terminal 
protein (TP) attached covalently (62). This protein protects the DNA from the 
endonucleases of the host cell. The genome is associated with other proteins like 
the basic protein VII and a small peptide termed mu (63), with the function to 
stabilize the DNA into the capsid. Another protein is packaged with the DNA, the 
protein V. This protein is attached to the genome on one side and on the other side 
to the capsid protein VI, so it links the viral DNA to the capsid (64). The virions 
contain also some copies of the adenovirus protease (Pr) that cleaves many of the  
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structural preproteins into their mature forms during the last stage of viral 
assembly. 
Since their discovery, more then 100 different species of adenoviruses have been 
identified from various species. In particular, human adenoviruses are classified 
into 6 subgroups (A-F), which are further subdivided into 51 serotypes (65).  
Among human adenoviruses, serotype 2 (Ad2) and serotype 5 (Ad5) of subgroup 
C are the most extensively studied.   
Once in contact with the target cell the adenovirus infection proceeds through two 
phases (Figure 7). 
 
 
Figure 7: Adenovirus entry into the host. The adsorption of the virus to target cell 
receptors involves high-affinity binding via the knob portion of the fibre. The prime 
receptor for human Adenovirus serotype 5 is identical to that for coxsackie B virus and 
has been named the coxsackie/Adenovirus receptor (CAR). After the attachment step, 
interaction between the penton base and v integrins on the cell surface leads to 
internalization of the virus through endocytosis. 
 
CHAPTER 1- INTRODUCTION 
 
20 
The first is named “early” phase and occurs in 6-8 hours. This phase comprises 
the entry of the virus into the host cell, the passage of the viral genome into the 
cytoplasm to the nucleus, the internalization of the adenoviral DNA into the 
nucleus and the transcription and translation of some viral genes, named early 
genes. These events modulate the cell metabolism to facilitate the replication of  
the virus DNA. The second phase is the “late” phase which can take about 4-6 
hours after the beginning of the transcription of the late genes. The initial 
attachment of the virion particles to the cell surface occurs through a high affinity 
binding between a portion of the fiber (knob domain) and a cell receptor. The first 
receptor identified was shown to be identical to that for Coxackie B virus and has 
therefore been termed Coxackie/adenovirus receptor (CAR) (66). CAR is a type I 
transmenbrane protein of 46 kDa belonging to the immunoglobulin superfamily 
which is present on the basolateral membrane of several epithelial cells in many 
tissues including heart, lung, liver and brain. All groups of adenoviruses use CAR 
for the adsorption of the virus to the target cell, except the adenoviruses of group 
B. These viruses bind another cellular receptor, the CD46, a complement 
regulatory protein. Therefore, the adenoviruses of group B are capable to infect 
some cells, like hematopoietic stem cells, dendritic cells and malignant tumor 
cells, which are resistant to the infection by the adenoviruses using CAR as the 
primary attachment receptor. All these data suggest that receptor recognition 
could be a key factor involved in cell tropism, to the point to to change it. The 
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adenovirus fiber can be modified by constructing chimeric viruses carrying fiber 
genes from different serotypes, or by binding the fiber with several antibodies (67 
68). After the initial attachment of the fiber knob portion to the cell surface, an 
RGD motif, exposed on the penton base (69), interacts with cellular v integrins 
(70), in presence of  divalent cations. In particular, the heterodimeric integrins, 
v3 and v5, support the adenovirus internalization playing an important role 
in the determination of the tropism. The interaction between adenovirus and 
plasma membrane can induce the activation of several signaling pathways like 
that of phosphoinositide-3-OH kinase (PI-3K), which triggers the Rho family of 
GTPases with consequential polymerization of actin and cythoscletal 
reorganization (71). Another pathway, activated 20 minutes post infection, is the 
Raf/Mitogen-activated protein kinase (MAPK) pathway, which culminates in the 
production of interleuchin 8 (IL-8) (72). Together, these events induce the 
adenovirus internalization through a clathrin-mediated endocytosis. In the acidic 
environment of the endosome, the virus-encoded protease mediates the 
dismemberment of the viral capsid through the proteolysis of the protein VI, 
which induces, in turn, the escape of virions to the cytoplasm. The passage 
through the cytoplasm to the nucleus seems to be mediated by the cellular protein 
p32 (73), which binds the virus core (constituted by the DNA and its associated 
proteins TP, mu, proteins VII and V), and involves dynein and microtubules (74). 
One hour after the infection, it is possible to detect the virion on the nuclear 
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matrix, where TP forms a complex with the cellular CAD pyrimidine synthesis 
enzyme (75) and p32 binds the nuclear lamin B to permit the dissociation between 
the viral DNA and the linked proteins. 
 
1.8.1 Early gene and DNA replication 
 
The transcription of adenoviral genes can be divided in two phases, early and late, 
occurring before or after viral DNA replication. The first viral transcribed gene is 
E1, which encodes for two products: E1A and E1B, each of them producing 
multiple proteins by way of differential mRNA processing. Two E1A transcripts 
are produced during early infection, encoding the 289R protein and 243R protein. 
These proteins have the function to modulate the cellular metabolism to make the 
cell more susceptible to virus replication. In order to do this, they act as trans-
activators on the other early adenovirus genes and induce the cells to enter in S 
phase (76). Indeed, both 289R and 243R protein are able to sequester Rb protein 
(Retinoblastoma protein), bounded to the transcriptional factor E2F, allowing the 
release of this factor and the activation of its target genes necessary for driving the 
cell into S phase (77). Moreover, E1A proteins can also bind proteins involved in 
the control of cell cycle, such as cyclin-dependent-kinase-inhibitor p21, or factors 
mediating chromatin structure like p400, pCAF and p300/CBP. The E1B gene 
product 55K (E1B-55K) acts blocking p53-dependent apoptosis by directly 
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binding p53, accumulated during cell cycle deregulation by E1A, and inhibiting 
its ability to induce expression of proapoptotic genes (78). Instead, the other 
product of E1B gene, E1B-19K, blocks the pathway of programmed cell death 
binding directly the proapoatotic proteins Bak and Bax (79). These mechanisms 
keep the cell alive as long as possible in order to permit the virus replication. The 
E2 gene products (E2A and E2B) are proteins that are necessary for the 
replication of viral genome and the ensuring transcription of late genes. The 
latters are a DNA polymerase, the preterminal protein (pTP) and the 72-kDa 
single stranded DNA binding protein (DBP). The E3 gene expression is 
indispensable for subverting the host defence mechanism, allowing the 
persistence of infected cells. Indeed, the E3-gp19K can interfere with the 
presentation of the viral antigen, preventing the translocation of MHC class I 
(major histocompatibily complex) molecules to the cell surface by sequestering 
them in the endoplasmic reticulum (80). Moreover, the E3-10.4K, 14.5K and 
14.7K proteins inhibit the apoptotic pathway inducing the clearance of TNF-, 
Fas ligand (FasL) and TRAIL receptors from the cell membrane. The gene 
products derived from the E4 cassette are involved in cell cycle control (E4orf6 
cooperates with the E1B-55K protein in the sequestration of p53), promote virus 
replication and shut-off the host protein synthesis (81). During the last steps of 
early phase of the adenovirus infection, the viral DNA replication begins but 
requires sequences within the ITRs as origin of replication. Moreover, because the  
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viral genome does not have telomeres, the integrity of DNA ends is ensured by 
the viral protein pTP. This protein is covalently linked to the 5’ end of each 
genome strand and acts as a primer for the viral DNA polymerase. The genes are 
encoded on both strands of DNA in a series of overlapping transcription units. 
 
1.8.2  Late gene expression and viral assembly 
 
After viral DNA replication, transcription of late genes begins. A key role in the 
control of this phase is played by the major late promoter (MLP), which is 
attenuated during the early stage of infection. In fact, during the “early phase”, the 
basal level of transcription is low while, after the viral DNA replication and the 
high expression of IVa2 and IX genes, the transcription via the MLP is fully 
functional. From the MLP, 5 genes (L1-L5) are transcribed as single pre-mRNAs, 
each one encoding from 15 to 20 different mRNAs by differential splicing and 
polyadenylation. These transcripts encode structural proteins and other proteins 
involved in virion assembly. The virion assembly takes place in the nucleus, but 
the hexon trimerization begins in the cytoplasm and, subsequently, the hexon 
trimers move to the nucleus where they are associated with pentons and minor 
proteins to form the capsid (82). The viral genome encapsidation requires the L1-
52/55K, IVa2, L4-33K proteins (83-85) and the packaging signal, which consists 
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in a series of seven repeats (A1-A7), enriched in AT, at the left end of the 
adenoviral DNA . These events are accompanied by changes in the nuclear 
structure. About 30 hours after infection, the host cell is lysed in a process 
involving the ADP protein (adenovirus death protein), a product of E3 gene, 
which is expressed only during the late phase of infection and is transcribed from 
MLP rather than E3 promoter (86). 
 
 
1.9 Adenoviral vectors  
 
 
Adenoviral vectors can be classified into first, second and third generation 
adenoviral vectors.  
To date, third generation adenoviral vectors (commonly named helper dependent 
adenoviral, HD-Ad vectors) are the most successfully devices used for systemic 
gene therapy since their safety profile is strongly superior if compared to first and 
second generation adenoviral vectors.  
First generation (FG-Ad) vectors are made by removing the E1 and/or E3 genes 
cassette. This genetic modification impairs the ability of virions to replicate and 
for this reason FG-Ad vectors are defined “replication-deficient adenoviral 
vectors, RDA”) (Figure 8). 
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Figure 8: FG-Ad vectors. FG-Ad vectors derive from the deletion of E1 and E3 
regions of the adenoviral backbone (white triangles). The structure of the wt 
adenovirus is reported for comparision. 
 
These vectors retain the ITRs, the packaging signal and the other genes whereas 
the E1/E3 cassettes are replaced by a transgene of 6-8 kb long, often under the 
control of a heterologous promoter. The production strategy of FG-Ad vectors 
consists in the generation of the adenoviral genome by homologous 
recombination between a backbone plasmid (pAdEasy), expressing all adenovirus 
genes except E1 and/or E3, and a plasmid shuttling the gene of interest. 
When the vector genome is cloned, its large scale production is made by 
transfecting the HEK-293 cell line, a human embryonic kidney-derived cell line, 
that provide the E1 functions in trans (87) (Figure 9). 
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Figure 9: FG-Ad vectors production. A plasmid expressing the transgene of interest 
(pShuttle) is recombinated with a backbone plasmid (pAdEasy), expressing all 
adenovirus genes except E1 and/or E3. After the homologous recombination, the pAd 
vector is linearized and tranfected in 293 cells to proceed with the large scale production 
of vector. 
 
Although FG-Ad vectors exhibit many advantages, as the ability to infect 
differentiated cells, liver tropism after systemic administration and high titer 
production (1x1013 vp/ml), some drawbacks are still present. The first is the 
possible recombination between the E1 region sequences in the packaging cells 
(HEK-293) and the recombinant virus during its rescue. This recombination event 
can generate a viral progeny with functional E1 genes that becomes replication 
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competent adenovirus (RCA). Despite this inconvenient, a second and more 
troublesome problem associated with the use of FG-Ad vectors consists in their 
stimulation of the host immune response. This response is due to low levels of 
vector replication, that can occur even in the absence of the E1 genes (88), 
resulting in the destruction of transduced cells and in the low persistence of 
transgene. 
In order to prevent these problems, second generation (SG-Ad) vectors have been 
proposed. These vectors are characterised by deletion of E2 and/or E4 coding 
sequences, providing both the benefits of a less probability of recombination to 
give RCA and a larger capacity for the transgene insertion (Figure 10).  
 
 
 
Figure 10: SG-Ad vectors. SG-Ad vectors derive from the deletion of E1, E2, E3, E4 
regions of the adenoviral backbone (white triangles). The structure of the wt adenovirus 
is reported for comparision. 
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Nevertheless, the inhibition of viral gene expression by E1 gene is not much 
efficient. For this reason, the host immune response is a major impediment in 
using these vectors for applications requiring long-term gene expression. 
Third generation, helper dependent adenoviral (HD-Ad) vectors are the product of 
the complete deletion of adenoviral wild type backbone, since they lack of both 
early and late genes and present only the ITRs and packaging signal of the wt 
adenovirus backbone (Figure 11). 
 
 
 
Figure 11: HD-Ad vectors. HD-Ad vectors derive from the deletion of all regions of the 
adenoviral backbone that are substituted with stuffer DNA (blue) and the expression 
cassette (red). The viral ITRs and the packaging signal (Ψ) are the only sequence of the 
wt adenoviral backbone that are still present in the construct (in black and grey 
respectively). 
 
 
As a result they have low toxicity, very high capacity, and do not elicit 
immunological responses against the vector, thus allowing prolonged transgene 
expression (59,60). 
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2. MATERIALS AND METHODS 
The research presented in this thesis required the use of many experimental 
methods. They are described in this chapter in detail. 
2.1 E.Coli XL10-Gold and BL21 competent cells 
production and transformation 
Rubidium chloride method for transformation competent cells 
Medium: LB broth 
TfbI, pH 5.8 with dilute acetic acid 
Potassium acetate 30 mM 
Rubidium chloride 100 mM 
Calcium chloride 10 mM 
Manganese chloride 50 mM 
Glycerol 15% (v/v) 
 
TfbII, pH 6.5 with dilute NaOH 
MOPS 10 mM 
Calcium chloride 75 mM 
Rubidium chloride 10 mM 
Glycerol 15% (v/v) 
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2 ml of an overnight culture of tetracycline/chloramphenicol resistant 
XL10-Gold (Stratagene, CA, U.S.A) or BL21 (Stratagene, CA, U.S.A) was 
inoculated into 200 ml LB broth (AppliChem, GmbH). Incubation at 37C was 
performed with aeration to an adsorption of A550 = 0.48. Then the suspension 
was kept on ice for 15 minutes. After that, the bacterial cells were aliquoted into 
50ml Falcon tubes and pelleted at 3000 rpm for 5 min at 4C. The supernatant 
was discarded, cells were resuspended in 20 ml TfbI (0.4V of the original 
volume) and iced for 15 minutes. Cells were again centrifuged at 3000rpm for 15 
min at 4C, then resuspended in 2 ml per Falcon tube of TfbII (0.04V of the 
original volume) and kept on ice for 15 min. For storage, cells were aliquoted in 
microfuge tubes (50l each), quick-frozen in a dry ice/ethanol bath and kept at -
80C. Competent XL10-Gold or BL21 cells were thawed on ice for 3 minutes, 
mixed by gentle tapping and briefly centrifuged at 3000rpm in a tabletop 
centrifuge. They were then resuspended by gentle pipetting, added to pre-chilled 
DNA and mixed either by tapping or gentle pipetting. A 30 minute incubation on 
ice after that was followed by a 45 seconds heat shock at 42C with gentle tapping 
once after 45 sec. Cells were then put directly on ice for 2 minutes. 0.5 ml of LB 
medium was added and the transformation reaction was kept in a shaker (300rpm) 
at 37C for 45 minutes. Following that, the volume was reduced by centrifugation 
and discarding of the supernatant to 150-200 l. Cells were then plated with a 
sterile glass spreader on pre-warmed LB-agar plates containing the respective 
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antibiotic. If -Galactosidase activity was used a selection marker, 40 l of X-Gal 
solution (AppliChem, GmbH) was added before plating. Plates were dried for 10 
minutes with an open lid at 37C and then incubated overnight. 
 
2.2 Construction of hPAH expression plasmid and site-
directed mutagenesis 
 
PAH wt and mutant constructs were obtained by modifying the plasmid pMAL 
Xa PAH, kindly provided by P. Waters (McGill University-Montreal Children’s 
Hospital Research Institute, Montreal, Canada) in order to digest the fusion 
protein MBP-hPAH with enterokinase. The plasmid was modified by introducing 
the enterokinase site downstream the sequence encoding the factor Xa site by site 
directed mutagenesis using the primers: 
5’GATGACGATGACAAGTCTACTGCGGTCCTGG3’ 
3’GCCCTAACTCCCTTCCCTACTGCTACTGTTC5’  
and Quick Site directed mutagenesis kit (Stratagene, CA, U.S.A). Subsequently, 
each mutation was introduced into pMAL Xa Ek PAH using mutagenic primers 
and Quick Site directed mutagenesis kit (Stratagene, CA, U.S.A) (Table 1). The 
modified plasmid and the resulting clones were sequenced to verify the 
introduction of each single mutation.  
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Mutation Mutagenic primer 5’ Mutagenic primer 3’ 
pN223Y catgaagattacattccccagctggaagac 
 
gtcttccagctggggaatgtaatcttcatg 
 
pR297L tgttttcagatctcagctttgcccagtttt 
 
aaaactgggcaaagctgagatctgaaaaca 
 
pF382L actgtcacggagttgcagcccctgtattac 
 
gtaatacaggggctgcaactccgtgacagt 
 
pK398N gccaaggagaacgtaaggaactttgctgcc 
 
ggcagcaaagttccttacgttctccttggc 
 
pQ419R acccatacacccgaaggattgaggtcttgg 
 
ccaagacctcaatccttcgggtgtatgggt 
 
pQ301P cgcagctttgccccgttttcccaggaaatt 
 
aatttcctgggaaaacggggcaaagctgcg 
 
pI65M acctgacccacatggaatctagaccttctc 
 
gagaaggtctagattccatgtgggtcaggt 
 
 
Table 1 List of the oligonucleotide primers used for site-directed mutagenesis. 
 
2.3 Expression and purification of hPAH in E.Coli 
 
Expression plasmids were transformed into BL21 cells and the colonies were 
selected using LB plates with ampicillin (0.1 mg/ml, AppliChem, GmbH). 
Bacteria were grown to 2 x 108 cells/ml (A600 ~0.5) and overexpression of wild-type 
and variant MBP-PAH fusion proteins was induced with 1 mM isopropylthio-b-
D-galactoside (IPTG, AppliChem, GmbH) for 16 hours. Cells were harvested by 
centrifugation and treated according to the instruction manual of pMAL protein 
fusion and purification system (New England Biolabs, MA, U.S.A.). The fusion 
protein was digested on and at room temperature with Enterokinase to obtain wt 
and mutant forms of PAH without MBP tag (New England Biolabs, MA, U.S.A.), 
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using 0.5 ng of enzyme for every 50 µg fusion protein. The mixture was then 
applied to a hydroxyapatite (Bio-Rad Laboratories, CA, U.S.A.) column (1 cm x 
10 cm) to remove maltose. MBP was isolated from the cleavage mixture by re-
binding to amylose resin and the tetrameric fusion protein was then collected by 
size-exclusion chromatography with a HiLoad 16/60 Superdex 200 column (GE 
Healthcare, U.K.). Protein concentrations were determined spectrophotometrically 
with the use of the absorption coefficient A280 or the dye-binding Bradford assay 
(Bio-Rad Laboratories, CA, U.S.A).  
 
2.4 Assay of PAH activity (purified proteins) 
 
For each wt and mutant form of PAH, the activity was assayed at 25 °C, as 
previously described (11). Briefly, 50 µl of standard reaction mixture contained 
0.1 M Na-Hepes, pH 7.0, 1 mg/ml of catalase, 100 mM ferrous ammonium 
sulphate, 5 mM DTT, 1 mM L-Phe, [14C] L-Phe (Amersham, Buckinghamshire, 
UK),  and 75 mM (6R)-tetrahydrobiopterin (BH4, Sigma-Aldrich, U.S.A). The 
enzyme (1-4, µg of hPAH) was preincubated for 2 min at 25° C in a mixture 
containing buffer, L-Phe and catalase. Then, Fe (II) was added and allowed to 
incubate for 1 min with the enzyme. The reaction was started by the addition of 
BH4 and DTT, and after 1 min was stopped by boiling. After centrifugation at 
room temperature and maximum speed, a 16 µl aliquot of supernatant was applied 
on a thin−layer chromatography (TLC, Polygram SIL N-HR/UV254 Macherey-
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Nagel, GmbH) system and the amount of 14C radiolabeled L-Phe converted to L-
Tyr was measured; the mean PAH activities were calculated from the three sets of 
protein preparations. The residual activities of mutant PAH enzymes were 
expressed as a percentage of wild type enzyme activity.  
 
2.5 Electrophoresis and immunoblotting 
 
SDS/PAGE was performed at 100 V (2 h) in a 10% (w/v) polyacrylamide gel; the 
purification of all proteins was verified after staining with Colloidal Comassie 
(Pierce, U.S.A.). The absence of MBP contamination in all preparations was 
determined by western blot analyses. Immunoblotting was performed using 
affinity-purified rabbit anti-human PAH (11) and mouse anti- MBP (New 
England Biolabs, MA, U.S.A.) as primary antibodies. The enhanced 
chemiluminescence (ECL) (Amersham, U.K.) was used for the immunodetection. 
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2.6 Generation and characterization of the HD-Ad 
vector 
 
hPAH cDNA was excised from the expression vector pcDNA3−PAH, kindly 
provided by Paula Waters, cloned into pGEM (Invitrogen, CA, U.S.A) and cut by 
NotI digestion (New England Biolabs, MA, U.S.A). It was then ligated with a 
NotI plasmid containing the PEPCK promoter, a fragment of the human ApoA−1 
intron and the bovine growth hormone polyadenylation signal. The expression 
cassette was excised from this plasmid by AscI digestion and cloned into p28, a 
plasmid containing the viral Ad ITRs (left ITR and packaging signals: 1−440 bp; 
right ITR: 35,535-35,935 bp, accession n.NC001406), the packaging signal and 
human stuffer DNA (the 15,730-26,835 BamHI fragment of the C346 cosmid, 
accession n.:L3948, and the 1799-17853 EclXI/PmeI fragment from the HPRTB 
gene, accession n.:HUMHPRTB), obtaining p28PEPCK PAH. 
A p28 carring the GFP sequence under the control of the CMV promoter was 
also constructed to follow the in vitro amplification of the vector.  
 The identity of both recombinant HD plasmids was confirmed by restriction 
enzyme digestion.  
HD-Ad DNA was released from p28PEPCKPAH and p28CMVGFP plasmids 
by digestion with PmeI (New England Biolabs, MA, U.S.A.) and produced 
according to the protocol described by Palmer and Ng with some modifications 
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aimed to rescue a higher amount of viral vector. The viral vector was then 
purified by two CsCl (Roche Diagnostic, GmbH ) step gradients and the HD-Ad 
band was collected and dialyzed. The virus suspension was taken out of the 
dialysis cassette (Pierce, U.S.A.) and 100 µl aliquots were stored at −80°C. The 
vector was quantified by OD260 determination. 
For structural characterization, DNA digested with KpnI (New England Biolabs, 
MA, U.S.A.) was run on an ethidium bromide – stained 1% agarose gel. For 
comparison, the parental plasmid was digested with PmeI in addition to the 
enzyme just named. For determination of helper contamination, DNA digested 
with PstI (New England Biolabs, MA, U.S.A) was transferred to a nylon 
membrane for Southern hybridization analysis (Hybond, Amersham Pharmacia 
Biotech). The [a-32P] dCTP random prime-labeled adenoviral packaging signal 
probe was used to distinguish between the 1.6-kb vector-specific and the 1.0-kb 
helper-specific bands. Helper contamination was also assessed by real time PCR, 
using the following primers: H1 FW: TGTGGGCCATATTTTTTGGG e H1 RW: 
CAGGCGAGCTTGTGTGGAG. The reaction was performed under the following 
conditions: at 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 95°C 
for 30 sec and 68°C for 30 sec. 
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2.7   Mouse injection and sample collection  
 
Breeding pairs of BTBR-Pahenu2 mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME, USA). A colony was maintained by mating 
heterozygote females with homozygous males in the Animal House at Ce.In.Ge, 
Biotecnologie Avanzate, Naples, to obtain sufficient numbers of Pahenu2 
homozygote mice for this study. Homozygous mice are distinguished from their 
heterozygous littermates by their lighter coat colour. The genotype was confirmed 
by restriction fragment length polymorphism analysis. The Pahenu2 mutation 
creates a new Alw26I restriction site in exon 7. Genomic DNA was extracted 
from tail samples and exon 7 of the PAH gene was amplified using primers in 
introns 6 and 7 with Taq polymerase (Applied Biosystem, U.S.A). The resulting 
PCR product was then overnight digested with Alw26I (Fermentas, U.S.A). The 
restriction fragments were separated by electrophoresis on a 2% agarose gel at 90 
V for 2 h. 
Mice were housed in groups (n=4-5) in standard cages (29x17.5x12.5 cm) at a 
constant temperature (22±1°C) and maintained on a 12 h light/dark cycle. They 
had unlimited access to water and a diet containing 18.0% protein without L-Phe  
restriction (4RFU, Mucedola s.r.l, Italy) throughout the whole experimental 
period. Three-week-old mice were injected with 1x1014 viral particles of HD-Ad-
PAH/kg into the tail vein. Blood samples were collected at various time points. 
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The liver, kidney, heart, and lungs were isolated from each HD-Ad injected 
Pahenu2 mice for analysis.  
Experiments were conducted in conformity with protocols approved by the 
veterinary department of the Italian Ministry of Health and in accordance with the 
ethical and safety rules and guidelines for the use of animals in biomedical 
research provided by the relevant Italian laws and European Union directives (n. 
86/609/EC). All efforts were made to minimize the animals’ suffering. All mice 
subjected to behavioural tasks were gently handled 5 min/d for 2 weeks before the 
experiments. 
 
2.8 Plasma Phe and Tyr tandem mass spectrometry 
determination 
 
Dried serum spots on filter paper were prepared by punching out a circle with a 
diameter of 3 mm. A total of 200 µl of MeOH containing internal labelled 
standards were added. The mixed contents were allowed to stand for 20 min at 
room temperature. The supernatant was transferred to an eppendorf, evaporated to 
dryness under nitrogen, and incubated with 80 µl of Butanol-HCl 3N at 65°C for 
25 min. The solvent was evaporated under nitrogen and the derivatized sample 
will be reconstituted in 300 µl of water-acetonitrile + 0.1% formic acid 50:50 
solution before injection in the API 2000 LC/MS/MS system. 
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2.9 Assay of PAH activity (eukariotic cell extracts) 
 
PAH enzyme activity assay was performed on the cytoplasmatic extracts of 116 
cells, infected with the HDAd-hPAH vector and collected two days after the 
transduction. The assay was conduced in a final volume of l00 µl containing 
10mM Tris HCl pH 7.4, 25 mM L-Phe, [14C] L-Phe, catalase, 100 µg of total 
protein extract and a BH4 solution containing DTT. The reaction was started by 
adding BH4−DTT, incubated at 25°C o.n., stopped by boiling for 5 min and 
centrifuged at room temperature and maximum speed. A 16 µl aliquote of 
supernatant was applied on a thin−layer chromatography system and run for about 
3 hours at room temperature in CHCl3−CH3OH−NH4OH−H20 (55:35:10 
vol/vol). Each amino acid spot was cut out, placed in a scintillation vial with 
liquid scintillant and measured for [14C] L-Phe and converted [14C] L-Tyr. 
  
2.10 Detection of HD-Ad DNA in tissues by Real Time 
PCR 
 
DNA was isolated from mouse organs by a proteinase K digestion/phenol 
extraction/ethanol precipitation method. The HD-Ad viral genomic DNA was 
detected by Real Time PCR using the primers: 28 FW: 
GGTGTCGATCCATACCCGC e 28 RW: GAGGGATAAGCATGGGCTGAC. 
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The reaction was performed under the following conditions: at 50°C for 2 min 
and 95°C for 10 min, followed by 40 cycles of 95°C for 30 sec and 68°C for 30 
sec. 
 
2.11 Behavioral tasks 
 
Two different tasks were used to assess the performances of PKU mice. The first 
and less invasive was the Morris water maze test. It was performed similarly to 
that described by Tang et al (89). The apparatus consisted of a circular pool (100 
cm in diameter), surrounded by three-dimensional visual cues, containing opaque 
water at 21±1°C with a platform (8 cm in diameter) submerged 1 cm beneath the 
water surface. The training phase consisted of two sessions per day (3 h interval 
between sessions) over a 5 d period. Each session was composed of four trials 
with an inter-trial interval of ~5 min. The time to reach the target was measured. 
A probe test was performed after training, 24 h after the last session (to evaluate 
time-dependent memory retention of mice), in which animals were allowed to 
swim for 60 s in the absence of the platform. The percentage of time spent in each 
quadrant was recorded. A computerized video tracking system (Videotrack; 
Viewpoint) was used to collect data during learning phase and probe test. In the 
learning phase, the measure of the escape latency was used as dependent variable, 
and data were examined using two-way ANOVA with repeated measures. Data 
obtained in the probe trials were analyzed by Fischer’s post hoc comparison, to 
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evaluate the spatial preference of each experimental group for each quadrant. 
Moreover, Student’s t test was used to determine genotype effect on the spatial 
preference. 
The Fear Conditioning was performed according to Shumyatsky et al. (90).  Mice 
were individually placed in a conditioning shock chamber (Freeze Monitor; San 
Diego Instrument). Conditioning was assessed 24 and 27 h after training by 
scoring freezing behavior, defined as the complete lack of movement. Contextual 
fear conditioning was evaluated and analyzed for 3 min in the context in which 
mice were trained, instead cued fear conditioning was assessed by masking the 
training context and subjecting mice to the cue (a 85 decibel sound). Both training 
and testing sessions were videotaped. Student’s t test was used to determine 
genotype effect on the freezing behavior, expressed as percentage of time spent in 
freezing. A significance level of p < 0.05 was accepted as statistically significant 
in all the experiments performed. All measures are expressed as mean ± SEM. All 
statistical analyses were performed with StatView software (version 5.0.1.0; SAS 
Institute). 
 
2.12 Electrophysiological studies 
 
All animals were studied using standard in vitro electrophysiological recordings. 
Preparation of hippocampal slices was performed in accordance with the 
European Communities Council Directive (86/609/EEC). Vibratome-cut 
CHAPTER 2- MATERIALS AND METHODS 
 
44 
parasagittal slices (400 µm) were prepared, incubated for one hour and then 
transferred to a recording chamber submerged in a continuously flowing artificial 
cerebrospinal fluid (30°C, 2-3 ml/min) gassed with 95% O2- 5% CO2. The 
composition of the control solution was (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2, 
1.2 NaH2PO4, 2.4 CaCl2, 11 Glucose, 25 NaHCO3. Field excitatory postsynaptic 
potentials (fEPSPs) were recorded in the stratum radiatum of the CA1 using glass 
microelectrodes (1–5MΩ) filled with aCSF. Synaptic responses were evoked by 
stimulation of the Schaffer collateral/commissural pathway with a concentric 
bipolar stimulating electrode. Data were expressed as mean ± SEM and assessed 
for significance using the Student’s t test or ANOVA, as appropriate. A minimum 
of 6 animals per group was used for all electrophysiological recordings. 
 
2.13 Expression of NMDA and AMPA receptor subunits 
by Western Blot 
 
BTBR-Pahenu2 were killed, the hippocampus was dissected out and immediately 
frozen. It was then homogenated in a buffer containing 2% SDS, 50 mM Tris-HCl 
pH 6.8, 1 mM EDTA, 1mM NaF, 1 mM NaVO3, 1x Complete Inhibitor (Roche 
Diagnostics, GmbH). Aliquots (2l) of the homogenate were used for protein 
determination using a Bio-Rad Protein Assay kit. Equal amounts of total proteins 
(30g) for each sample were loaded onto 10% polyacrylamide gels. Proteins were 
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separated by SDS-PAGE and transferred overnight to membranes (polyvinylidene 
difluoride) (GE Healthcare, U.K.). 
The membranes were immunoblotted using selective antibodies against NR2B, 
(1:1000; Millipore, MA, U.S.A), NR2A (1:1000, Sigma-Aldrich, U.S.A.), Glu1 
(1:1000, Sigma-Aldrich, U.S.A), Glu2/3 (1:1000, Sigma-Aldrich, U.S.A), and 
GAPDH (1:6000; Santa Cruz, CA, U.S.A.). Blots were then incubated in 
horseradish peroxidase conjugated secondary antibodies, and target proteins were 
visualized by ECL detection (GE Healthcare, U.K.), followed by imaging using a 
Bio-Rad Chemidoc instrument with quantitation by Quantity One software. 
Optical density values were normalized to GAPDH for variations in loading and 
transfer. Normalized values were then averaged and used for statistical 
comparisons (Student’s t test). 
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During my PhD, I treated two different aspects of PKU. The first regarded the 
characterization of new mutant forms of the PAH enzyme that were identified in 
Italian PKU patients.  
The other aspect was the cure of the pathologic phenotype of PKU by means of a 
HD-Ad vector expressing PAH. I delivered the wild type PAH gene to the hepatic 
tissue of PKU mice that after the treatment showed a complete normalization of 
their pathologic biochemical features.  
I also studied the behavioural profile of these mice to investigate if an early 
treatment with gene therapy could ameliorate their behavioural pathologic 
phenotype.  These studies were integrated by electrophysiological analyses and 
by the determination of the expression levels of N-methyl-D-aspartic acid 
(NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)  
receptor subunits that, as known, play a pivotal role in learning and memory 
processes and which were found to be imbalanced in PKU. 
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3. RESULTS 
 
3.1 Mutagenesis and Expression in E.Coli of wild type 
and mutant forms of PAH 
 
All the mutations analyzed have been previously expressed in human HEK293 
cells using transient expression (10-12). As the amount of protein obtained in the 
eukaryotic system is not enough to consent a suitable purification and 
characterization of the molecular features of the PAH enzyme, recombinant 
proteins were produced in the prokaryotic system, using E.Coli BL21 cells.  
The first step consisted in the introduction of the enterokinase site downstream the 
sequence encoding the factor Xa site in pMAL Xa PAH, in order to digest the 
fusion protein MBP-hPAH with enterokinase (Figure 12). In fact, it has been 
demonstrated that the cleavage of MBP-hPAH with factor Xa releases not only 
the full-lenght product but also a truncated form of the protein, lacking the 13 N-
terminal residues, thus indicating that  factor Xa digestion occurred also between 
the residues Arg- 13 and Lys-14 in the hPAH sequence. In this conditions, the 
recovery of  full-length hPAH varied depending on the reaction temperature and 
time, as well as the protein:protease ratio (92). This problem is avoided when 
enterokinase is used. Indeed, the fusion protein MBP-Ek-hPAH is specifically 
cleaved by enterokinase at its target sequence (D4K) and only full-length hPAH 
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resulted from this cleavage. The introduction of the enterokinase site was done by 
site directed mutagenesis and confirmed by DNA sequencing.  In the same way, 
all mutations were introduced into  pMAL Xa Ek PAH and confirmed by 
sequence analysis. 
After all the purification steps described in the Materials and Methods section, 
wild type and mutants PAH pure proteins were obtained in proper amounts (8-10 
mg/liter of culture). An exception was represented by the Q301P mutant which 
showed a different behaviour and was recovered in lower amounts.  
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Schematic representation of pMAL Xa Ek PAH.The Xa and Ek sites are 
shown in blue and red respectively. The MBP and PAH gene are represented in grey and 
purple.   
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3.2 Electrophoresis and immunoblotting 
 
The purity of all proteins was verified by SDS/PAGE followed by Colloidal 
Comassie staining. As shown in Figure 13, a band corresponding to the molecular 
weight of PAH monomer was present.  
 
Figure 13: SDS PAGE analysis of purified hPAH by Colloidal Comassie staining. 
Lane1 contains the protein stained marker; Lane 2: hPAH after the FPLC purification 
step. 
 
 
The further confirmation that this band contained only PAH and not MBP was 
obtained by Western Blot. Immunoblotting performed using affinity-purified 
rabbit anti-human PAH and mouse anti- MBP showed that the purified protein did 
not contain any MBP trace, so confirming that the product was highly pure 
(Figure 14). 
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Figure 14: Western blot analysis performed on the hPAH wt protein. Lane1 contains 
the protein stained marker. Lane 2: immunoblotting using anti-hPAH as primary 
antibody. Lane 3 contains the same protein blotted with anti-MBP antibody.  
 
3.3   Enzymatic activity analysis of wild type and mutant 
forms of PAH 
 
PAH enzyme assay was performed after enterokinase digestion and purification of 
wt and mutant proteins. All mutants showed a residual lower activity compared to 
wt PAH. For all mutations, the enzyme activity measured in the prokaryotic 
system corresponded to those observed in human HEK293 cells (10-12). 
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3.4   Generation and characterization of the HD-Ad 
vector 
 
A HD-Ad vector was constructed by inserting the human PAH-cDNA into the 
p28 vector plasmid, as described in the Materials and Methods section. This 
vector, p28-hPAH, contained the phosphoenolpyruvate carboxykinase (PEPCK) 
promoter, the apoA1 intron, the hPAH cDNA and the GH polyA signal (Figure 
15 A). The PEPCK promoter was inserted in the HD-Ad construct for its liver 
specificity in order to restrict the expression of the hPAH in the liver, the target 
tissue of the PKU disease.  
After several passages of HD-Ad amplification in adhesion/suspension culture of 
116 cells, the viral vector was rescued by CsCl gradient (Figure 15 B) and 
subjected to further studies to evaluate its structure and helper contamination. 
As depicted in Figure 15 C, restriction digestion analysis of the vector and the 
parental plasmid DNA showed the expected bands and excluded gross vector 
rearrangements during rescue.  Southern Blot analysis confirmed that the 
preparation was free of helper virus (Figure 15 D). This result was further 
confirmed by real-time PCR that showed a 0.06% of helper contamination. The 
vector was then tested for its in vitro ability to express a functional PAH protein 
before the in vivo studies.  
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Figure 15: Structure and characterization of HDAd-hPAH vector. (a) Diagram of the 
vector used in this study: the HDAd-hPAH contains, in the pΔ28 backbone, the liver-
restricted phosphoenolpyruvate carboxykinase (PEPCK) promoter, the human ApoAI 
intron,  the hPAH cDNA and the human growth hormone poly A. (b) Purification of the 
vector by CsCl gradient following the final amplification of the vector in a suspension 
culture of 116 cells. The top band is of empty capsids, the more dense of HDAd-hPAH. 
(c) Restriction digests with Kpn1/Pme1 of parental plasmid (lane 1), HD-Ad hPAH (lane 
2) and helper virus (lane 3) DNAs. The overlap between the structure of the plasmid and 
the viral vector indicates absence of gross vector rearrangements. (d) Analysis of helper 
virus contamination. The DNAs were digested and hybridized with the L-ITR plus the 
packaging signal sequence that give fragments of different length for the HDAd vector 
and the helper virus. Lane1: Pme1/Pst1 digested pΔ28 plasmid; Lane 2: Pme1/Pst1 
digested pΔ28-PEPCK-hPAH plasmid; Lane 3: Pst1 digested Helper virus; Lane 4: Pst1 
digested HDAd-hPAH. 
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A HD-Ad vector expressing GFP was used to monitor the amplification of the 
HD-Ad vector expressing PAH and was produced at the same time (Figure  16). 
 
 
Figure 16: Amplification of a HDAd vector expressing GFP. Several passages (from 
transfection of the viral plasmid to suspension culture of infected cells) are showed. 
During each of these steps, the amount of viral vector expressing GFP rapidly increases. 
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3.5 Activity assay of HDAd-hPAH after in vivo 
transduction 
 
116 cells were infected with the HDAd-hPAH vector and used for the in vitro 
assay, as described in the Materials and Methods section. Two days after the 
infection, HDAd-hPAH transduced cells were collected and cytoplasmatic 
proteins were isolated. Cells transduced with a control plasmid (pCDNA3-PAH) 
and untransduced cells were used as positive and negative controls respectively.  
As shown in Figure 17, PAH activity was found both in the pCDNA3-PAH and 
HDAd-hPAH transduced cells but there was no expression in the untransduced 
cells. The lower signal for HD-Ad hPAH transduced cells could be explained on 
the basis of the liver specific promoter present in the viral construct. 
 
Figure 17: in vitro PAH activity assay by TLC. The PAH activity was assessed 48 
hours after the transduction of 116 cells to evaluate the effectiveness of the viral construct 
in the expression and activity of hPAH. In the TLC system, Phe has a higher RF than Tyr. 
Assays were conduced in the presence of BH4 cofactor. Lane A) represents untransduced 
cells lane B) pCDNA3-PAH transduced cells and lane C) HDAd-hPAH transduced cells.  
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3.6 Effects of adenoviral treatment on 
hyperphenylalaninemia 
 
Purified HD-Ad hPAH was used to treat 3-week-old BTBR PAHenu2 mice, by 
means of a single intravenous injection. To achieve phenotypic correction of PKU 
homozygous BTBR PAHenu2 mice, whose basal Phe and Tyr values were 
respectively 1200 M and 25 M , different doses of HD-Ad vector were tested, 
starting from 1x1013 viral particles (vp)/kg (n=3), increasing to 3x1013 vp/kg 
(n=3), and finally using a maximum dose of 1x1014 vp/kg (n=3) per animal. This 
pilot experiment allowed us to estabilish that serum Phe and Tyr levels were 
unchanged in mice treated with the lowest dose of the viral vector, whereas, mice 
treated with the intermediate dose reached the normal values (80 M) in two 
weeks but increased four weeks after the treatment. Only mice treated with the 
highest dose obtained a normalization of Phe and Tyr two weeks and was stably 
maintained for all the observation period (Figure 18 A,B). For this reason, 3x1012 
vp were used for the successive studies.  
 
 
 
 
CHAPTER 3- RESULTS 
 
57 
 
Figure 18: Time course of serum Phe and Tyr levels in PKU mice after intravenous 
administration of vector HDAd-hPAH. PKU mice ( ) showed a severe 
hyperphenylalaninemia (Panel A) and a decrease of Tyr levels (B) before the treatment. 
This biochemical phenotype was rescued in HDAd-hPAH treated PKU mice ( ). 
Control mice were indicated as ( ). Serum Phe and Tyr levels at various time points 
after HDAd-hPAH injection were compared with pre-injection levels using Student’s t-
test. Significant differences as compared to t = 0 found for all HDAd-hPAH treated 
animals were found at all time points. 
 
 
 
CHAPTER 3- RESULTS 
 
58 
Together with the normalization of Phe values, HD-Ad PAH treated mice showed 
a reversal of their hypopigmentation. In particular, visible changes started 1week 
after the injection of the viral vector and became complete 2 weeks after the 
treatment (Figure 19 A,B). Treated homozygous BTBR PAHenu2 mice remained 
indistinguishable from wild-type and heterozygous mice over the whole 
experimental period.  
 
 
Figure 19: Coat color change in PKU mice after the administration of the vector. 
Owing to a reduction in serum Tyr, the precursor of melanin, PKU mice present a grey 
coat (A). The characteristic hypopigmentation of PKU coat was completely reversed 2 
weeks after the administration of the vector (B). 
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3.7  Effects of the adenoviral treatment on in vivo PAH 
enzymatic activity 
 
A restoration of PAH enzymatic activity was observed 2 and 6 months after the 
administration of the vector in PKU mice (Figure 20). PAH activities recovered 
to levels ranging from 15% to 20% of wild-type mice.  
 
 
Figure 20: in vivo PAH activity assay by TLC. Levels of PAH enzyme activities were 
assessed in the liver of PKU HDAd-hPAH treated mice 6 months after the administration 
of the vector. Lane 1 shows untreated PKU mice, lanes 2-3 control mice, lanes 4-6 viral 
treated mice. 
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3.8    Detection of HDAd-hPAH DNA by Real Time PCR 
 
Tissue distributions of recombinant adenovirus were examined in PKU mice. The 
amount of viral DNA was quantified by Real Time PCR. The majority of the 
recombinant virus was found in the liver. Viral DNA was also detected, in much 
lower quantities in the spleen, kidney, lung, heart and was undetectable in brain 
(Figure 21).  
 
Figure 21: Detection of HD-Ad DNA in HDAd-hPAH tissue samples. The distribution 
of the viral vector was assessed by real time pcr in tissue samples taken from HDAd-
hPAH treated mice. The HD vector DNA is particular abundant in the liver. Lung, heart, 
kidney are only marginally infected, instead in the brain the HD vector DNA is 
completely absent. 
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3.9    Behavioural tasks 
 
It is established that NMDA receptors signalling plays a pivotal role in 
hippocampus related learning and memory. Thus, based on the evidence that Phe 
can inhibit the correct function of NMDA receptors, acting as an antagonist of the 
co-activator glycin (21,22), and supported also by other studies that showed 
behavioural deficits in the PKU mouse model, we assessed the performances of 
mice in two tasks: the Morris Water Maze and the Fear Conditioning.  
The first experiments were performed with homozygous BTBR Pahenu2 mice and 
healthy controls, represented by heterozygous mice, that, as known, present 
normal levels of L-Phe. 
We used only the Morris Water Maze was to explore the performances of HD-Ad 
treated PKU mice, since Fear conditioning was not a good task to evaluate the 
performances of these mice. In fact, freezing behaviour of both homozygous and 
heterozygous BTBR Pahenu2 mice was extremely reduced if compared to other 
strains (for example C57/BL6 mice), especially in the cue-version (Figure  22 
A,B).  
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Figure 22: Fear conditioning of homozygous PKU (red bars) mice versus control  
(blue bars) mice. The performances of both groups of mice revealed a poor freezing 
behaviour.  
 
 
The Morris Water Maze task was performed in two versions: a visible and a 
hidden platform version. The first was made to exclude any emotional, sensory 
and/or motor impairments in this animal model (Figure 23 A). In the hidden 
version, on the other hand, PKU mice revealed a deficit in spatial learning that 
was recovered in HD-Ad treated PKU mice that showed a profile comparable to 
control, heterozygous mice (Figure 23 B). This reflected also in the spatial 
memory profile, with a higher percentage of time spent in the goal quadrant for 
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HDAd-hPAH treated and heterozygous mice compared to PKU mice that did not 
display a particular quadrant preference (Figure 23 C). 
 
Figure 23: Correction of reference memory in 2 month-HDAd-hPAH treated mice. 
The Morris Water Maze task was used to evaluate reference memory impairments of 
PKU mice ( ). The task was done in two versions (visible and hidden platform 
training). In the visible platform training, PKU mice displayed similar performances if 
compared to viral treated ( ) and control ( ) littermates. In the hidden platform 
training, instead, PKU mice performed considerably worse than viral treated and control 
mice. Similar results were seen in the probe test, in which PKU mice ( , C) displayed 
deficits in spatial memory compared to control ( ,C) and viral treated mice ( ,C).  
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The same effect was found in PKU mice that were treated for a longer period with 
the HDAd-hPAH vector (Figure 24 A,B,C). 
 
 
Figure 24: Correction of reference memory in 6 month-HDAd-hPAH treated mice. 
The Morris Water Maze task was repeated in another group of HDAd-hPAH injected 
mice, 6 months after the treatment, to confirm the benefic effect of the HDAd-hPAH 
vector in PKU mice.  As for the 2 month-groups, untreated PKU mice displayed similar 
performances if compared to viral treated ( ) and control ( ) mice (A) in the 
visible platform training, whereas they showed deficits in spatial learning ( , B) and 
memory ( , C) in the hidden version. HdAD-hPAH treated PKU mice, injected at 3 
weeks of age, showed a rescue of the behavioral pathologic phenotype ( ,B) ( ,C).  
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3.10     Electrophysiological studies 
 
In order to verify if the memory deficits observed in homozygous PKU mice 
correlate with defects in synaptic plasticity, the electrophysiological phenotype of 
these mice in the Schaffer collateral pathway was explored by recording 
extracellular field potentials.  
No significant difference in stimulus-response curves and in paired-pulse 
facilitation (PPF) between homozygous PKU and heterozygous control mice were 
found (data not shown), indicating that basal transmission was not affected by the 
mutation. 
To determine whether synaptic plasticity might be altered in the same 
experimental groups, we studied long-term potentiation (LTP) induced by a high-
frequency stimulation protocol (HFS). Stimulation at 100 Hz induced a severe 
deficit in LTP in brain slices from homozygous PKU mice compared to 
heterozygous control mice (50–60 min: heterozygous mice: 150% ± 10%; 
homozygous mice: 122% ± 10%, p < 0.05; Figure 25 A).  
Starting from these data, we tested whether this deficit could be overcome by 
gene therapy and we found that LTP levels in HD-Ad treated mice were restored 
upon the treatment (50–60 min: viral, 141% ± 3%, p < 0.05; Figure 25 B).  
Our results, summarized in Figure  25 C, indicate that gene therapy was able to 
reverse the deficit in synaptic plasticity observed in PKU mice. 
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Figure 25: Effect of L-Phe on the modulation of hippocampal synaptic functions at 
CA1 synapses. A) Superimposed pooled data showing the normalized changes in field 
potential slope (±SEM) in homozygous PKU mice (white plots)  vs heterozygous control 
mice (black plots) induced by HFS protocol. The degree of potentiation between 50-60 
min after HFS was significantly lower in homozygous PKU (n = 7) compared to 
heterozygous (n = 6) mice. fEPSP slopes were recorded and were expressed as the 
percentage of the pretetanus baseline. A stimulation intensity that evoked 50% of 
maximal fEPSP response was used. B) Superimposed pooled data showing the effects of 
viral treatment on LTP in homozygous PKU mice (n = 8, red plots). C) Columns 
represent the average EPSP response measured between 50-60 min following HFS 
(asterisk indicates p < 0.05). 
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3.11   Expression of NMDA and AMPA receptor subunits 
by Western Blot 
 
Expression analysis of NMDA receptor subunits in homozygous PKU mice 
showed an imbalance between NR2A and NR2B subunits, with an increased 
expression of NR2A subunit and a significant decreased expression of NR2B 
subunit.  
On the other hand, western blot analysis of  both GluR1 and GluR2/3 subunits of 
AMPA receptors revealed an up-regulation of GluR1 and GluR2/3 subunits that 
was particularly significant for GluR2/3.  
As depicted in Figure 26, HDAd-hPAH treated mice presented a normalization of 
the expression of these subunits. 
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Figure 26: Expression analysis of NMDA and AMPA receptor subunits in HDAd-
hPAH treated mice. Control mice are showed in grey, homozygous PKU mice in green 
and HDAd-hPAH treated mice are depicted in red. Panel A shows NR2A subunit, panel 
B NR2B, panel C Glu1 and panel D Glu2/3 subunit. 
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4 DISCUSSION 
 
Gene therapy for PKU patients could be a promising approach to prevent brain 
damage due to discontinuation of the arduous dietary restriction treatment. 
Several types of vectors, including retroviral, first generation adenoviral, and 
adeno-associated viral gene transfer vectors, have been examined for their 
potential to transduce liver, the prominent site of PAH expression and activity 
(51-56). In this context, adenovirus mediated gene therapy holds a significant 
potential thanks to the ability of adenoviral vectors to transduce the hepatic tissue. 
Nevertheless, the clinical translation of adenoviral gene replacement therapy for 
genetic disease is lagged by vector associated toxicity that is very significant for 
first and second generation adenoviral vectors (87). In fact, a previous attempt to 
cure PKU by means of a first generation adenoviral vector expressing PAH was 
successful but did not produce a long lasting effect due to the strong immune 
response that followed the administration of this type of adenoviral vector (51). 
Advances in vector production have led to the development of Helper-Dependent 
adenoviral vectors (HD-Ad) which are characterized by the deletion of all viral 
coding genes, so the chronic toxicity that follow their systemic administration is 
significantly reduced (59-60).  
In this thesis, I have described a gene therapy approach based on a helper 
dependent adenoviral vector expressing PAH that was administered to 3-week-old 
PKU mice that, before the treatment, showed a severe hyperphenylalaninemia. 
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Serum Phe levels were measured at different time points to follow the 
biochemical correction mediated by the therapeutic helper dependent adenoviral 
vector. The decrease in serum Phe levels was accompanied by an increase of Tyr 
levels that, as is known, is the precursor of neurotrasmitters and melanin. As a 
consequence, gene therapy treated mice started to change their grey coat color one 
week after the administration of the vector and became completely black two 
weeks after the treatment. By the way, the biochemical correction was only one of 
our objectives. In fact, we addressed our attention also on the effects of gene 
therapy on the neurological impairments of PKU mice. 
It has been previously reported that PKU mice present behavioural deficits 
involving both spatial and non-spatial recognition that are not related to motor 
impairments or to high emotional reactivity to novelty (45).  
Moreover, the authors that delivered the first generation adenoviral vector 
expressing PAH to PKU mice (52) noticed that gene therapy treated mice were 
more alert than their untreated counterparts, although they did not elucidate their 
phenotypic changes with behavioural studies. Later, other investigators (89) 
performed a behavioural characterization of gene therapy treated mice but they 
assessed only their locomotion and exploratory behaviour.  
As the evaluation of the behavioural and neurological parameters in PKU mice 
after gene therapy could provide important experimental evidences for the 
efficacy of the proposed treatment, we deeply investigated the performances of 
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PKU mice. At this aim, we used the Morris Water Maze task, a procedure 
designed to explore the role of hippocampus in the formation of spatial memory. 
We observed a strong deficit in spatial learning and memory in untreated PKU 
mice that was completely reversed in HD-Ad treated mice, both at 2 and at 6 
months of treatment.  
It is known that glutamatergic synaptic is altered in PKU. Acute application of L-
Phe at concentrations observed in the PKU brain depressed the glutamatergic 
synaptic transmission but did not affect GABA receptor activity in cultured 
neurons (21).   
The same authors assessed also the effect of high L- Phe levels in vivo, in the 
forebrain tissue from heterozygous and  homozygous PKU mice (22). Consistent 
with the depressant effects of L-Phe, expression of NMDA receptor NR2A and 
(RS)–amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor 
Glu1 and Glu2/3 subunits was significantly increased in PKU mice, whereas 
expression of NR2B subunit was decreased.  
In particular, it is thought that the increase in NR2A/NR2B ratio may contribute 
to the precocious ageing of  PKU brain.  
Starting from this, we assessed the expression levels of these receptor subunits in 
untreated, gene therapy treated and control mice. We confirmed the imbalance in 
the expression of NMDA and AMPA receptor subunits but obtained significant 
differences (p<0.05) only for NR2B and Glu3. Viral treated mice showed a 
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normalization of the altered expression of these subunits, supporting a role of Phe 
in the upregulation/downregulation of NMDA and AMPA receptor subunits. 
The activation of NMDA receptors is also known to be involved in long-lasting 
modifications in synaptic efficiency, namely long-term potentiation (LTP) and 
long-term depression (LTD), that are classically regarded as the substrate for 
learning and memory (93). Consistent with the involvement of iGluRs in the 
cognitive impairment of PKU, we studied NMDA-dependent LTP in the mouse 
model of PKU. Our results show a severe deficit in LTP in hippocampal slices 
from homozygous PKU mice that parallels our behavioural studies. Intriguingly, 
this impairment is restored upon viral treatment, supporting the beneficial effect 
of gene therapy. 
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During the last year of my PhD, I was involved in another project regarding 
PKU, that’s the characterization of new mutant forms of the PAH enzyme that 
were identified in PKU patients. 
This project is still in progress and our objectives are not only the correlation of 
the altered chemical physical properties of these mutants to the loss of PAH 
function but also the identification of new potential therapeutic agents that, 
stabilizing these mutant forms, may be useful to treat PKU patients.  
A general problem faced with in the characterization of mutant forms of hPAH 
leading to PKU and hyperphenylalaninaemias, has so far been the expression of 
the full-length mutant enzymes in sufficient quantities. 
To date, we have set up the system to produce high amounts  of  pure proteins for 
biophysical characterizations.  
We have conduced some studies regarding their detailed structural and functional 
properties that have revealed differences among wild type PAH and its mutants. 
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